Alzinova

Alzinovas VD Tord Labuda kommer att presentera bolaget och berätta om de senaste framstegen klockan 16.15. Eventet, som äger rum den 28 november, kommer att livesändas och Alzinovas presentation går att se på Carnegies hemsida live via:
https://api.screen9.com/preview/rj7Ag6BV21XolqtLUk1TY3nkYyQAUCQ5Q-_TgJSheoBCVHn--X12WWMybx-PCq96

Presentationen kommer även att finnas på Alzinovas hemsida i efterhand via följande länk: https://www.alzinova.com/investors/presentations/.

För ytterligare information, vänligen kontakta:
Tord Labuda, VD
E-post: tord.labuda@alzinova.com

About Alzinova
Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com